Erick Riquelme

Erick Riquelme

Auto-generated profile, based on publicly available information

Erick Riquelme

Pontifical Catholic University of Chile 13 Respiratory Diseases Department, Faculty of Medicine Santiago, Chile

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2019 in Cell
Verified
Journal Article
Closed access
ERErick Riquelme
Erick Riquelme
YZYu Zhang
Yu Zhang
LZLiangliang Zhang
Liangliang Zhang
MMMaria Montiel
Maria Montiel
MZMichelle Zoltan
Michelle Zoltan
FMFlorencia McAllister
Florencia McAllister

28 August 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
YZYu Zhang
Yu Zhang
VCVidhi Chandra
Vidhi Chandra
ESErick Riquelme Sanchez
Erick Riquelme Sanchez
PDPrasanta Dutta
Prasanta Dutta
PQPompeyo R. Quesada
Pompeyo R. Quesada
FMFlorencia McAllister
Florencia McAllister
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal malignancy with an immunosuppressive microenvironment that is resistant to most therapies. IL17 is involved in pancreatic tumorigenesis, but its role in invasive PDAC is undetermined. We hypothesized that IL17 triggers and sustains PDAC immunosuppression. We inhibited IL17/IL17RA signaling using pharmacological and genetic strategies alongside mass cytometry and multiplex immunofluorescence techniques. We uncovered that IL17 recruits neutrophils, triggers neutrophil extracellular traps (NETs), and excludes cytotoxic CD8 T cells from tumors. Additionally, IL17 blockade increases immune checkpoint blockade (PD-1, CTLA4) sensitivity. Inhibition of neutrophils or Padi4-dependent NETosis phenocopies IL17 neutralization. NMR spectroscopy revealed changes in tumor lactate as a potential early biomarker for IL17/PD-1 combination efficacy. Higher expression of IL17 and PADI4 in human PDAC corresponds with poorer prognosis, and the serum of patients with PDAC has higher potential for NETosis. Clinical studies with IL17 and checkpoint blockade represent a novel combinatorial therapy with potential efficacy for this lethal disease.

5 June 2024 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
SPSusana Castro Pando
Susana Castro Pando
RHRian M. Howell
Rian M. Howell
LLLe Li
Le Li
MMMarilina Mascaró
Marilina Mascaró
EFErika Y. Faraoni
Erika Y. Faraoni
FMFlorencia McAllister
Florencia McAllister
IL17 is required for the initiation and progression of pancreatic cancer, particularly in the context of inflammation, as previously shown by genetic and pharmacological approaches. However, the cellular compartment and downstream molecular mediators of IL17-mediated pancreatic tumorigenesis have not been fully identified. This study examined the cellular compartment required by generating transgenic animals with IL17 receptor A (IL17RA), which was genetically deleted from either the pancreatic epithelial compartment or the hematopoietic compartment via generation of IL17RA-deficient (IL17-RA−/−) bone marrow chimeras, in the context of embryonically activated or inducible Kras. Deletion of IL17RA from the pancreatic epithelial compartment, but not from hematopoietic compartment, resulted in delayed initiation and progression of premalignant lesions and increased infiltration of CD8+ cytotoxic T cells to the tumor microenvironment. Absence of IL17RA in the pancreatic compartment affected transcriptional profiles of epithelial cells, modulating stemness, and immunological pathways. B7-H4, a known inhibitor of T-cell activation encoded by the gene Vtcn1, was the checkpoint molecule most upregulated via IL17 early during pancreatic tumorigenesis, and its genetic deletion delayed the development of pancreatic premalignant lesions and reduced immunosuppression. Thus, our data reveal that pancreatic epithelial IL17RA promotes pancreatic tumorigenesis by reprogramming the immune pancreatic landscape, which is partially orchestrated by regulation of B7-H4. Our findings provide the foundation of the mechanisms triggered by IL17 to mediate pancreatic tumorigenesis and reveal the avenues for early pancreatic cancer immune interception. See related Spotlight by Lee and Pasca di Magliano, p. 1130

22 November 2024 in Briefings in Bioinformatics
Verified
Journal Article
Open access
LMLeandro Murgas
Leandro Murgas
GPGianluca Pollastri
Gianluca Pollastri
ERErick Riquelme
Erick Riquelme
MVMauricio Alejandro Sáez Venegas
Mauricio Alejandro Sáez Venegas
AMAlberto J. Martin
Alberto J. Martin
Structural changes of chromatin modulate access to DNA for the molecular machinery involved in the control of transcription. These changes are linked to variations in epigenetic marks that allow to classify chromatin in different functional states depending on the pattern of these histone marks. Importantly, alterations in chromatin states are known to be linked with various diseases, and their changes are known to explain processes such as cellular proliferation. For most of the available samples, there are not enough epigenomic data available to accurately determine chromatin states for the cells affected in each of them. This is mainly due to high costs of performing this type of experiments but also because of lack of a sufficient amount of sample or its degradation. In this work, we describe a cascade method based on a random forest algorithm to infer epigenetic marks, and by doing so, to identify relationships between different histone marks. Importantly, our approach also reduces the number of experimentally determined marks required to assign chromatin states. Moreover, in this work we have identified several relationships between patterns of different histone marks, which strengthens the evidence in favor of a redundant epigenetic code.

26 June 2026 in Cancer Discovery
Verified
Journal Article
Open access
HLHaoyue Liu
Haoyue Liu
JJJeong-Hoon Jang
Jeong-Hoon Jang
FPFuduan Peng
Fuduan Peng
HRHajar Rajaei
Hajar Rajaei
VCVidhi Chandra
Vidhi Chandra
FMFlorencia McAllister
Florencia McAllister
Tumor microbes are increasingly recognized for modulating tumor behavior and therapy responses. Intratumoral microbial burden (ITMB) analysis across cancers revealed regulation of immune pathways and activated mast cells, mostly in colorectal and gastric cancers. High-ITMB colorectal cancer leads to interferon (IFN) regulation and is associated with improved outcomes in advanced disease. Single-cell sequencing revealed induction of IFN-related genes (IRG) within microbe-containing human colorectal cancer. Gastrointestinal-luminal mismatch repair–deficient (MMRd) tumors had higher ITMB than proficient tumors. In a rectal MMRd cohort with 100% remission after immune checkpoint blockade (ICB), tumor microbes and microbe-containing mast cells increased. In ICB-sensitive syngeneic murine MMRd tumor models, local tumor microbial depletion impaired ICB efficacy while downregulating IFN signaling. Forced upregulation of IRGs in ADAR1-deficient cancer cells restored immunotherapy responses during microbial ablation. These data highlight dynamic interplay among ITMB, host defense, and immunogenicity, which seems key to determine therapy responses. Significance: The ITMB is linked to transcriptional and immune functional changes that seem to determine tumor sensitivity to immunotherapy. These findings highlight the key role of tumor-resident microbes in shaping the tumor ecosystem, which could be targeted to modulate therapy responses.